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Background: The risk of secondary malignancies (SM) is
increased in long-term survivors of allogeneic hematopoietic
stem cell transplantation (SCT). There is limited literature on
squamous cell carcinoma (SCC) of head and neck post-SCT.
We report a single center series of 6 patients (pts) who
developed SCC of oral cavity or esophagous during remission
after SCT.
Methods: This IRB approved retrospective analysis reviewed
charts of adult pts who had undergone SCT and subse-
quently developed SCC. Patients were identiﬁed by review-
ing BMT data base and data was collected from medical
records.
Results: Six patients (Table 1), median age 40 yrs (31-54) at
SCT were diagnosed with SCC in a median follow up of 8 yrs
(3-13). Five out of 6 pts developed SCC of tongue and 1
developed esophageal SCC. Five pts had chronic GVHD but
had no history of alcohol or tobacco use except 1 pt (pt 6)
who had remote history of smoking/alcohol use. Human-
papilloma virus was negative on the tumor samples. All pts
had chronic inﬂammation, pain and intermittent ulcerations.
New onset of oral pain was the main symptom in pts who
developed oral SCC. Clinically oral SCC lesions look similar to
chronic GVHD lesions. Three pts developed recurrences and
2 died of metastatic SCC.
RIC indicates reduced intensity conditioning, MSD matched
sibling donor, MUD matched unrelated donor, LVI lympho-
vascular invasion, PNI perineural invasion, SD squamous
dysplasia, NPB no prior biopsy, NA not applicable, NP not
performed, C cyclosporine, P prednisone, M mycophenolate
mofetil, R Rituximab, Ph photopheresis.
Conclusion: Ourobservation shows that the SCCof oral cavity
is a common SM in post-SCT patients. SCC was often multi-
focal, negative surgical margin was difﬁcult to obtain and
employing standard therapy was difﬁcult due to concomitant
severe chronic GVHD. The SCC lesions were clinically indis-
tinguishable from chronic GVHD lesions and the only pre-
senting clinical symptom was a new onset of persistent oral
pain from a non-healing GVHD-like lesion. Since SCC in this
setting can mimick a GVHD lesion, a non-healing oral lesionTable 1
Characteristics of squamous cell carcinoma in survivors of SCT
Patient Age at
SCT/sex
Primary
Hematologic
malignancy
Type of SCT Site/stage of SCC
1 46M Non-Hodgkin’s
Lymphoma
RIC MSD Right tongue, left
ﬂoor of mouth, pT1N0
2 40M AML Ablative MSD Base of tongue and
left tonsil, pT1N1
3 35F AML Ablative MSD Left tongue, pT2N0
4 54F CML Ablative MSD Right tongue, pT4aN2b
5 42M CML Ablative MSD Tip of the tongue, pT1N
6 31M CML Ablative MSD Gastroesophageal junct
stage IIIAshould not be assummed to be chronic GVHD. Such lesions
should be evaluated in consultation with ENT and a biopsy
considered to rule out SCC.
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Patients with metastatic or refractory sarcomas have a
dismal prognosis with 5-year survival of 10-20%. Clinical
trials with anti-IGF-1R (insulin-like growth factor-1 recep-
tor) antibody in patients with refractory Ewing sarcoma
(EWS) have produced low response rate (10-14%), which
exemplify the need to develop new therapies. We hypoth-
esize that IGF-1R chimeric antigen receptor (CAR) T cells
may be more effective than antibody as they kill IGF-1R+
sarcomas even at a low level of expression. To test our hy-
pothesis, we transfected peripheral blood lymphocytes
from 6 healthy donors and 3 sarcoma patients with Sleeping
Beauty (SB) transposons encoding IGF-1R CAR with a 4-1BB
signaling domain and GFP (IG) or GFP:Zeocin fusion gene
(IGZ) and SB100X transposase-expressing plasmids and
selected for GFP or drug resistance. 51Cr-release assays
demonstrated the cytotoxicity of IGF-1R CAR T cells against
a panel of IGF-1R+ sarcoma cell lines including 2 osteosar-
coma (OS), 3 alveolar rhabdomyosarcoma (ARMS), 2
embryonal rhabdomyosarcoma (ERMS),1 ﬁbrosarcoma (FS),
and 1 EWS. CAR T cells were not cytotoxic for IGF-1R- K562
erythroleukemia and Daudi lymphoma cells and unmodi-
ﬁed T cells did not kill IGF-1R+ target cells (Fig. 1A). CAR T
cells also killed human IGF-1R cDNA transfected mouse
embryonal ﬁbroblast cells derived from IGF-1R knockout
mice but not parental cells. In addition, we also demon-
strated expression of the alternative target ROR1(receptor
tyrosine kinase-like orphan receptor 1) in 13 of 17 sarcoma
cell lines tested as it has been shown that ROR1 is highlyResection
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